359 related articles for article (PubMed ID: 29392441)
1. Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.
Astaras C; de Micheli R; Moura B; Hundsberger T; Hottinger AF
Curr Neurol Neurosci Rep; 2018 Feb; 18(1):3. PubMed ID: 29392441
[TBL] [Abstract][Full Text] [Related]
2. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
Sato K; Mano T; Iwata A; Toda T
J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
[TBL] [Abstract][Full Text] [Related]
3. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
Pan PC; Haggiagi A
Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
[TBL] [Abstract][Full Text] [Related]
4. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
5. Neurologic complications of immune checkpoint inhibitors.
Fellner A; Makranz C; Lotem M; Bokstein F; Taliansky A; Rosenberg S; Blumenthal DT; Mandel J; Fichman S; Kogan E; Steiner I; Siegal T; Lossos A; Yust-Katz S
J Neurooncol; 2018 May; 137(3):601-609. PubMed ID: 29332184
[TBL] [Abstract][Full Text] [Related]
6. [Toxicity of immune checkpoints inhibitors].
Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
[TBL] [Abstract][Full Text] [Related]
7. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
[TBL] [Abstract][Full Text] [Related]
8. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
Papouin B; Mussini C; De Martin E; Guettier C
Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
Plachouri KM; Vryzaki E; Georgiou S
Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
[TBL] [Abstract][Full Text] [Related]
10. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.
Vogrig A; Muñiz-Castrillo S; Farina A; Honnorat J; Joubert B
J Neurol; 2022 Mar; 269(3):1701-1714. PubMed ID: 34708250
[TBL] [Abstract][Full Text] [Related]
11. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.
Dalvin LA; Shields CL; Orloff M; Sato T; Shields JA
Retina; 2018 Jun; 38(6):1063-1078. PubMed ID: 29689030
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
13. [Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors].
Seki M; Suzuki S
Brain Nerve; 2021 Jan; 73(1):35-46. PubMed ID: 33361512
[TBL] [Abstract][Full Text] [Related]
14. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
Seki M; Kitano S; Suzuki S
Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
[TBL] [Abstract][Full Text] [Related]
15. Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.
Kao JC; Brickshawana A; Liewluck T
Curr Neurol Neurosci Rep; 2018 Aug; 18(10):63. PubMed ID: 30078154
[TBL] [Abstract][Full Text] [Related]
16. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer.
Sebastiani GD; Scirocco C; Galeazzi M
Autoimmun Rev; 2019 Aug; 18(8):805-813. PubMed ID: 31176871
[TBL] [Abstract][Full Text] [Related]
17. Enterocolitis due to immune checkpoint inhibitors: a systematic review.
Soularue E; Lepage P; Colombel JF; Coutzac C; Faleck D; Marthey L; Collins M; Chaput N; Robert C; Carbonnel F
Gut; 2018 Nov; 67(11):2056-2067. PubMed ID: 30131322
[TBL] [Abstract][Full Text] [Related]
18. Neurologic complications of immune checkpoint inhibitors.
Hottinger AF
Curr Opin Neurol; 2016 Dec; 29(6):806-812. PubMed ID: 27653290
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sandigursky S; Mor A
Curr Rheumatol Rep; 2018 Sep; 20(10):65. PubMed ID: 30191417
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.
Yshii LM; Hohlfeld R; Liblau RS
Nat Rev Neurol; 2017 Dec; 13(12):755-763. PubMed ID: 29104289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
